Recent General News

Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment

(November 28, 2018)

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker... Continue Reading


Patients with rare, incurable digestive tract cancers respond to new drug combination

(November 19, 2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some... Continue Reading


New Treatment Approved for Influenza

(October 26, 2018)

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients aged ≥12 years old who have been symptomatic for no more... Continue Reading


AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer

(September 4, 2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the... Continue Reading


FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

(August 2, 2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and... Continue Reading


FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

(May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra... Continue Reading


FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches

(May 21, 2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million... Continue Reading


What is a Venous Access Device and What Types are Used for Cancer Patients?

(May 9, 2018)

A venous access device (VAD) is a surgically implanted device that provides long-term access to a major vein. A VAD can be useful for patients undergoing systemic treatment with precision cancer medicines... Continue Reading


Lutathera Pepetide Receptor Radionuclide Therapy for NETs

(May 3, 2018)

CancerConnect News: Lutathera (lutetium Lu 177 dotatate) was recently approved for the treatment of neuroendocrine tumors (NETs) that typically occur in the pancreas and gastrointestinal tract. This is... Continue Reading


CancerConnect – Online Support & Networking for Cancer Patients

(March 21, 2018)

Social networking sites are rapidly growing, giving patients with cancer a place to connect with others. On line social groups on Facebook, discussion boards, and peer to peer networking connections have... Continue Reading


Next Page »